SG11202105355XA - Crystalline salts of corydalmine - Google Patents

Crystalline salts of corydalmine

Info

Publication number
SG11202105355XA
SG11202105355XA SG11202105355XA SG11202105355XA SG11202105355XA SG 11202105355X A SG11202105355X A SG 11202105355XA SG 11202105355X A SG11202105355X A SG 11202105355XA SG 11202105355X A SG11202105355X A SG 11202105355XA SG 11202105355X A SG11202105355X A SG 11202105355XA
Authority
SG
Singapore
Prior art keywords
corydalmine
crystalline salts
crystalline
salts
Prior art date
Application number
SG11202105355XA
Other languages
English (en)
Inventor
Zheng Yang
Zheng Jane Li
Hongju Yang
Zhicong Shi
Original Assignee
Zheng Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zheng Yang filed Critical Zheng Yang
Publication of SG11202105355XA publication Critical patent/SG11202105355XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202105355XA 2018-11-29 2019-11-15 Crystalline salts of corydalmine SG11202105355XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2018/118203 WO2020107335A1 (en) 2018-11-29 2018-11-29 Crystalline salts of corydalmine
PCT/CN2019/118903 WO2020108330A1 (en) 2018-11-29 2019-11-15 Crystalline salts of corydalmine

Publications (1)

Publication Number Publication Date
SG11202105355XA true SG11202105355XA (en) 2021-06-29

Family

ID=70851885

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105355XA SG11202105355XA (en) 2018-11-29 2019-11-15 Crystalline salts of corydalmine

Country Status (8)

Country Link
US (1) US11236081B2 (zh)
EP (1) EP3887367A4 (zh)
JP (1) JP7194828B2 (zh)
CN (1) CN111788201B (zh)
AU (1) AU2019385971B2 (zh)
CA (1) CA3121405C (zh)
SG (1) SG11202105355XA (zh)
WO (2) WO2020107335A1 (zh)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280827A (zh) * 1999-01-04 2001-01-24 中国科学院成都生物研究所 含一类生物碱的σ受体作用药
CN1164759C (zh) * 2002-09-29 2004-09-01 中国药科大学 紫堇达明的生物转化制备方法及其在制备镇痛药中的应用
CN1726990A (zh) * 2005-07-26 2006-02-01 中国人民解放军军事医学科学院基础医学研究所 含有效生物碱的天然中草药在戒毒药中的应用及提取工艺
US8003795B2 (en) 2007-06-22 2011-08-23 Cvi Pharmaceuticals Limited Compounds and compositions for reducing lipid levels
CN103214477A (zh) * 2013-05-08 2013-07-24 中国药科大学 一种利用碱化硅胶分离紫堇达明生物碱的工艺
CN105566316A (zh) * 2014-10-17 2016-05-11 刘力 二苯并喹嗪类化合物实体及其用途
CN106176740B (zh) * 2016-07-01 2019-02-26 北京泰舟利泽医药科技有限公司 紫堇达明抗成瘾的医药用途
CN106237333A (zh) 2016-07-08 2016-12-21 杨征 紫堇达明的医药用途
CN107260738A (zh) 2017-07-11 2017-10-20 上海华堇生物技术有限责任公司 紫堇达明碱的药物用途

Also Published As

Publication number Publication date
US11236081B2 (en) 2022-02-01
US20210347770A1 (en) 2021-11-11
EP3887367A1 (en) 2021-10-06
CN111788201A (zh) 2020-10-16
JP7194828B2 (ja) 2022-12-22
CA3121405A1 (en) 2020-06-04
JP2022509701A (ja) 2022-01-21
CN111788201B (zh) 2021-12-28
CA3121405C (en) 2024-01-02
AU2019385971A1 (en) 2021-06-10
EP3887367A4 (en) 2022-12-28
AU2019385971B2 (en) 2022-11-03
WO2020108330A1 (en) 2020-06-04
WO2020107335A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
IL276644A (en) crystalline forms
IL268852A (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitantane
IL269626A (en) Crystalline salt forms of BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2
PT3577125T (pt) Formas cristalinas de tenofovir alafenamida
SI3380554T1 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
HK1244274A1 (zh) C21h22ci2n4o2的晶型
PL3529236T3 (pl) Krystaliczne formy erawacykliny
PL3532457T3 (pl) Postacie krystaliczne hydroksynorketaminy
IL260004A (en) Crystalline forms of quinolone analogs and their salts
IL269073A (en) Crystalline forms of obeticholic acid
IL253479A0 (en) Crystalline forms of efinconazole
SI3749673T1 (sl) Kristalinična oblika biktegravir natrija
EP3793980A4 (en) CRYSTALLINE FORM OF S-APOMORPHINE
IL270961A (en) Crystalline form of N-butyldeoxygalactonogirimycin
IL269792B (en) Crystalline forms of (s)–apoxolner
HK1246786A1 (zh) 吡咯並吡啶化合物的結晶形式
IL274758A (en) Crystalline forms of praquinostat
GB201912411D0 (en) Crystalline forms of ivosidenib
IL272835A (en) Salts of a compound and crystalline forms thereof
IL278054A (en) The crystalline forms of a compound
HK1252841A1 (zh) 噻吩並嘧啶化合物的鹽酸鹽的結晶形式
SG11202105355XA (en) Crystalline salts of corydalmine
EP3511317A4 (en) NEW CRYSTALLINE SODIUM SALT FORM OF SACUBITRIL
GB201915908D0 (en) Crystalline forms of entrectinib
IL270937A (en) Crystalline forms of saltalicib